Company Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction.
Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Faraz Ali M.B.A. |
Contact Details
Address: 171 Oyster Point Blvd., Suite 500 South San Francisco, California 94080 United States | |
| Phone | 415-865-2066 |
| Website | tenayatherapeutics.com |
Stock Details
| Ticker Symbol | TNYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001858848 |
| CUSIP Number | 87990A106 |
| ISIN Number | US87990A1060 |
| Employer ID | 81-3789973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Faraz Ali M.B.A. | Chief Executive Officer, Secretary and Director |
| Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board and Director |
| Dr. Timothy Hoey Ph.D. | Chief Scientific Officer |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dr. Bruce R. Conklin | Scientific Founder |
| Dr. Saptarsi Haldar M.D. | Scientific Founder |
| Dr. Sheng Ding Ph.D. | Scientific Founder |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder |
| Leone D. Patterson M.B.A. | Chief Financial and Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | ARS | Filing |
| Apr 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2024 | 10-K | Annual Report |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 144 | Filing |
| Feb 20, 2024 | 144 | Filing |
| Feb 16, 2024 | 144 | Filing |
| Feb 16, 2024 | 144 | Filing |
| Feb 16, 2024 | 144 | Filing |